首页> 外文期刊>Experimental Eye Research >FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue
【24h】

FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue

机译:Fty720改善Nod小鼠的干眼症:白细胞抑制和脚卵细胞再生在眼表面组织中的参与

获取原文
获取原文并翻译 | 示例
           

摘要

FTY720 is a promising drug in attenuating multiple sclerosis, prolonging survival of organ allograft, and many other protective effects. Its mechanism of action is considered to be mediated by the internalization of sphingosine 1-phosphate receptors (S1PRs). In the current study, we investigated the efficacy of FTY720 in Non-Obese Diabetic (NOD) mice, serving as a model of Dry Eye Disease (DED). NOD mice were divided into six study groups, i.e., FTY720-treated groups with 3 concentrations of FTY720 (0.05%, 0.005%, and 0.001%), 0.05% Cyclosporin A (CsA) treated group, normal saline treated group, and no treatment control group. FTY720 was reconstituted with normal saline and prepared as eye drop. The stability and production of tear film was measured by Tear Break up Time test (TBUT) and phenol red cotton thread test (PRCTT), respectively. Tear fluid washings were collected and assessed by ELISA. Cytokines were detected in lacrimal glands by RT-PCR. Inflammation in conjunctiva was assessed by immunohistochemistry, goblet cells and conjunctival epithelia were examined and evaluated by impression cytology. Our results indicated that FTY720 had a significantly therapeutic effect in NOD mice. After FTY720 intervention, TBUT and PRCTT data were greatly improved (p < 0.01), the interleukin 1 beta (IL-1 beta) level was markedly decreased in tear fluid washings compared to control and normal saline groups after 2 weeks (Control: 1.06 +/- 0.12, Normal saline:0.97 +/- 0.09 pg/ml, CsA:0.22 +/- 0.02 pg/ml, 0.001% FTY720:0.23 +/- 0.02 pg/ml, 0.005% FTY720:0.14 +/- 0.03 pg/ml, 0.05% FTY720: 0.18 +/- 0.03 pg/ml. CsA group and 3 FTY720 groups VS. control group and normal saline groups: p < 0.01). Proinflammatory factors were greatly decreased in lacrimal glands (p < 0.01). Leukocytes were identified and markedly decreased in conujnctiva (p < 0.01), inflammatory reaction of DED was greatly relieved. More importantly, the goblet cells were largely restored and ocular surface lesions were significantly ameliorated (p < 0.01). Thus, we observed FTY720 alleviated DED in NOD mice by inhibiting leukocytes, the function of ocular surface tissue in NOD mice was partially restored via inhibiting ocular surface inflammation and increasing the density of goblet cells and conjunctival epithelia. FTY720 may offer a novel strategy for the treatment of inflammatory disorders in the ocular surface. (C) 2015 Elsevier Ltd. All rights reserved.
机译:Fty720是一种有希望的药物,用于衰减多发性硬化,延长器官同种异体移植的生存以及许多其他保护作用。其作用机制被认为是通过鞘氨醇1-磷酸盐受体的内化(S1PRS)介导的。在目前的研究中,我们研究了FTY720在非肥胖糖尿病(NOD)小鼠中的功效,作为干眼症(DED)的模型。将小鼠分为六个研究组,即Fty720处理的基团,具有3个浓度的Fty720(0.05%,0.005%和0.001%),0.05%环孢菌素A(CSA)处理的组,生理盐水处理组,无需治疗控制组。 FTY720用生理盐水重构并准备滴眼液。撕裂膜的稳定性和生产分别通过撕裂分段时间测试(TBUT)和酚红棉螺纹试验(PRCTT)测量。收集泪液水洗并通过ELISA评估。通过RT-PCR在泪腺中检测细胞因子。通过免疫组织化学评估结膜炎的炎症,通过印模细胞学检查和评估脚卷细胞和结膜上皮细胞。我们的结果表明,FTY720在NOD小鼠中具有显着的治疗效果。在FTY720干预后,TBUT和PRCTT数据大大改善(P <0.01),与2周后的对照和生理盐水基团相比,白细胞介素1β(IL-1β)水平显着降低(对照:1.06 + / - 0.12,正常盐水:0.97 +/- 0.09 pg / ml,CSA:0.22 +/- 0.02 pg / ml,0.01%Fty720:0.23 +/- 0.02 pg / ml,0.005%Fty720:0.14 +/- 0.03pg / ml,0.05%FTY720:0.18 +/- 0.03 pg / ml。CSA组和3个FTY720组对照组和生理盐水组:P <0.01)。泪腺的促炎因子大大降低(P <0.01)。在Conujnctiva(P <0.01)中鉴定了白细胞并显着降低,DED的炎症反应大大缓解。更重要的是,高脚卷细胞大大恢复,并且眼表面病变显着改善(P <0.01)。因此,我们观察到通过抑制白细胞,通过抑制白细胞,通过抑制白细胞,通过抑制眼表面炎症并增加高杯细胞和结膜上皮的密度部分恢复NOD小鼠中的眼部组织的功能。 FTY720可以提供一种用于治疗眼表面炎症疾病的新策略。 (c)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号